Ironwood Pharmaceuticals Shares Rise 10% on Positive Results in Bowel Disease Study

Dow Jones

2024/10/28

By Jasmine Li

Shares of Ironwood Pharmaceuticals rose after it reported positive trial results for its treatment for short bowel syndrome with intestinal failure.

The gastrointestinal healthcare company's stock rose 10.6% to $4.38 in premarket trading Monday. Shares had previously hit a 52-week low of $3.79 in August.

Boston-based Ironwood said Monday morning the phase 3 trial for its apraglutide treatment showed consistent effects for adults across demographics. The trial also showed consistent effects on patients with varying lengths of remnant bowel, which is notable as this characteristic significantly impacts treatment and prognosis, the company said.

SBS-IF affects an estimated 18,000 adult patients in the U.S., Europe and Japan, according to Ironwood. Apraglutide is the first investigational once-weekly GLP-2 analog to successfully demonstrate positive results in a phase 3 placebo-controlled study, the company said.

Ironwood said it expects to complete U.S. regulatory submission in the first quarter of 2025.

Write to Jasmine Li at jasmine.li@wsj.com

(END) Dow Jones Newswires

October 28, 2024 08:09 ET (12:09 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2478104478"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2478104478\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2478104478?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-28 20:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2478104478","market":"us","top_or_hot":-1,"title":"Ironwood Pharmaceuticals Shares Rise 10% on Positive Results in Bowel Disease Study","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Jasmine Li \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Ironwood Pharmaceuticals rose after it reported positive trial results for its treatment for short bowel syndrome with intestinal failure. \n</p>\n<p>\n  The gastrointestinal healthcare company's stock rose 10.6% to $4.38 in premarket trading Monday. Shares had previously hit a 52-week low of $3.79 in August. \n</p>\n<p>\n  Boston-based Ironwood said Monday morning the phase 3 trial for its apraglutide treatment showed consistent effects for adults across demographics. The trial also showed consistent effects on patients with varying lengths of remnant bowel, which is notable as this characteristic significantly impacts treatment and prognosis, the company said. \n</p>\n<p>\n  SBS-IF affects an estimated 18,000 adult patients in the U.S., Europe and Japan, according to Ironwood. Apraglutide is the first investigational once-weekly GLP-2 analog to successfully demonstrate positive results in a phase 3 placebo-controlled study, the company said. \n</p>\n<p>\n  Ironwood said it expects to complete U.S. regulatory submission in the first quarter of 2025. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Jasmine Li at jasmine.li@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 28, 2024 08:09 ET (12:09 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ironwood Pharmaceuticals Shares Rise 10% on Positive Results in Bowel Disease Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIronwood Pharmaceuticals Shares Rise 10% on Positive Results in Bowel Disease Study\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2024-10-28 20:09</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Jasmine Li \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Ironwood Pharmaceuticals rose after it reported positive trial results for its treatment for short bowel syndrome with intestinal failure. \n</p>\n<p>\n  The gastrointestinal healthcare company's stock rose 10.6% to $4.38 in premarket trading Monday. Shares had previously hit a 52-week low of $3.79 in August. \n</p>\n<p>\n  Boston-based Ironwood said Monday morning the phase 3 trial for its apraglutide treatment showed consistent effects for adults across demographics. The trial also showed consistent effects on patients with varying lengths of remnant bowel, which is notable as this characteristic significantly impacts treatment and prognosis, the company said. \n</p>\n<p>\n  SBS-IF affects an estimated 18,000 adult patients in the U.S., Europe and Japan, according to Ironwood. Apraglutide is the first investigational once-weekly GLP-2 analog to successfully demonstrate positive results in a phase 3 placebo-controlled study, the company said. \n</p>\n<p>\n  Ironwood said it expects to complete U.S. regulatory submission in the first quarter of 2025. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Jasmine Li at jasmine.li@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 28, 2024 08:09 ET (12:09 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2478104478","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478104478","pubTimestamp":1730117340,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Ironwood Pharmaceuticals rose after it reported positive trial results for its treatment for short bowel syndrome with intestinal failure.The gastrointestinal healthcare company's stock rose 10.6% to $4.38 in premarket trading Monday. Shares had previously hit a 52-week low of $3.79 in August.Boston-based Ironwood said Monday morning the phase 3 trial for its apraglutide treatment showed consistent effects for adults across demographics. The trial also showed consistent effects on patients with varying lengths of remnant bowel, which is notable as this characteristic significantly impacts treatment and prognosis, the company said.SBS-IF affects an estimated 18,000 adult patients in the U.S., Europe and Japan, according to Ironwood. Apraglutide is the first investigational once-weekly GLP-2 analog to successfully demonstrate positive results in a phase 3 placebo-controlled study, the company said.Ironwood said it expects to complete U.S. regulatory submission in the first quar","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IRWD":"Ironwood医药"},"translate_title":"肠道疾病研究取得积极结果，Ironwood Pharmaceuticals股价上涨10%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRWD":1},"content_text":"By Jasmine Li \n\n\n \n\n\n  Shares of Ironwood Pharmaceuticals rose after it reported positive trial results for its treatment for short bowel syndrome with intestinal failure. \n\n\n  The gastrointestinal healthcare company's stock rose 10.6% to $4.38 in premarket trading Monday. Shares had previously hit a 52-week low of $3.79 in August. \n\n\n  Boston-based Ironwood said Monday morning the phase 3 trial for its apraglutide treatment showed consistent effects for adults across demographics. The trial also showed consistent effects on patients with varying lengths of remnant bowel, which is notable as this characteristic significantly impacts treatment and prognosis, the company said. \n\n\n  SBS-IF affects an estimated 18,000 adult patients in the U.S., Europe and Japan, according to Ironwood. Apraglutide is the first investigational once-weekly GLP-2 analog to successfully demonstrate positive results in a phase 3 placebo-controlled study, the company said. \n\n\n  Ironwood said it expects to complete U.S. regulatory submission in the first quarter of 2025. \n\n\n \n\n\n  Write to Jasmine Li at jasmine.li@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 28, 2024 08:09 ET (12:09 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}